US › Healthcare

Aardvark Therapeutics, Inc. Common Stock (AARD)

US · Healthcare · Biotechnology

$5.53+7.38%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.4M

EPS

$-0.66

EPS estimate

$-0.87

EPS came in at -0.66 against a street estimate of -0.87 — a beat of 24.1%.

Key statistics

Market cap

$112.3M

Forward P/E

0.0

P/B

1.47

Book value

$3.42

EPS (TTM)

$-3.25

52-week high

$17.94

52-week low

$3.35

50-day MA

$6.31

200-day MA

$7.89

Analyst view

Analysts rate Aardvark Therapeutics, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $11.11.

Shareholding

Insiders

16.12%

Institutions

52.59%

Largest institutional holders

Fund	Stake
Decheng Capital LLC	17.90%
Citadel Advisors Llc	5.68%
LAURION CAPITAL MANAGEMENT LP	4.73%
BlackRock Inc	3.62%
Vanguard Capital Management, LLC	2.53%
EcoR1 Capital, LLC	1.81%
Geode Capital Management, LLC	1.41%
Adage Capital Partners Gp LLC	1.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aardvark Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.